Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

1.

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups.

Haematologica. 2011 Oct;96(10):1470-7. doi: 10.3324/haematol.2011.044933. Epub 2011 Jun 17.

2.

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups.

Blood. 2011 Feb 10;117(6):1799-805. doi: 10.1182/blood-2010-04-277434. Epub 2010 Dec 8.

3.

Myeloproliferative disorder in Noonan syndrome.

Bastida P, García-Miñaúr S, Ezquieta B, Dapena JL, Sanchez de Toledo J.

J Pediatr Hematol Oncol. 2011 Jan;33(1):e43-5. doi: 10.1097/MPH.0b013e3181e7571e.

PMID:
20829714
4.

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups.

Blood. 2010 Jun 24;115(25):5137-46. doi: 10.1182/blood-2010-01-266007. Epub 2010 Apr 14.

5.

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.

Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM; Programa Español de Tratamiento en Hematologia Group.

Haematologica. 2010 Apr;95(4):589-96. doi: 10.3324/haematol.2009.014274. Epub 2010 Feb 9.

6.

Genetic changes including gene copy number alterations and their relation to prognosis in childhood acute myeloid leukemia.

Armengol G, Canellas A, Alvarez Y, Bastida P, Toledo JS, Pérez-Iribarne Mdel M, Camós M, Tuset E, Estella J, Coll MD, Caballín MR, Knuutila S.

Leuk Lymphoma. 2010 Jan;51(1):114-24. doi: 10.3109/10428190903350397.

PMID:
20001230
7.

Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, del Potro E, Abella E, Bueno J, Parody R, Bastida P, Grande C, Heras I, Bethencourt C, Feliu E, Ortega JJ.

J Clin Oncol. 2008 Apr 10;26(11):1843-9. doi: 10.1200/JCO.2007.13.7265.

8.

Presenting features of 201 children with acute lymphoblastic leukemia: comparison according to presence or absence of ETV6/RUNX1 rearrangement.

Alvarez Y, Caballín MR, Gaitán S, Pérez A, Bastida P, Ortega JJ, Cervera J, Verdeguer A, Tasso M, Aventín A, Badell I, Guitart M, Melo M, Granada I, Javier G, Dastugue N, Robert A, Coll MD.

Cancer Genet Cytogenet. 2007 Sep;177(2):161-3. No abstract available.

PMID:
17854676
9.

[Vancomycin-resistant Enterococcus faecium bacteremia in Spanish pediatric intensive care unit].

Soler Palacín P, Peña Y, Pujol M, Bastida P.

Med Clin (Barc). 2007 Jun 16;129(3):116. Spanish. No abstract available.

PMID:
17594864
10.

Study of the genotype-phenotype relationship in four cases of congenital erythropoietic porphyria.

To-Figueras J, Badenas C, Mascaró JM, Madrigal I, Merino A, Bastida P, Lecha M, Herrero C.

Blood Cells Mol Dis. 2007 May-Jun;38(3):242-6. Epub 2007 Jan 31.

PMID:
17270473
11.

Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial.

Ribera JM, Ortega JJ, Oriol A, Bastida P, Calvo C, Pérez-Hurtado JM, González-Valentín ME, Martín-Reina V, Molinés A, Ortega-Rivas F, Moreno MJ, Rivas C, Egurbide I, Heras I, Poderós C, Martínez-Revuelta E, Guinea JM, del Potro E, Deben G.

J Clin Oncol. 2007 Jan 1;25(1):16-24.

12.

Genetic abnormalities associated with the t(12;21) and their impact in the outcome of 56 patients with B-precursor acute lymphoblastic leukemia.

Alvarez Y, Coll MD, Ortega JJ, Bastida P, Dastugue N, Robert A, Cervera J, Verdeguer A, Tasso M, Aventín A, Guitart M, Caballín MR.

Cancer Genet Cytogenet. 2005 Oct 1;162(1):21-9.

PMID:
16157196
13.

Sterile neonatal pustulosis associated with transient myeloproliferative disorder in twins.

Viros A, Garcia-Patos V, Aparicio G, Tallada N, Bastida P, Castells A.

Arch Dermatol. 2005 Aug;141(8):1053-4. No abstract available.

PMID:
16103349
14.

ETV6/RUNX1 rearrangement in childhood B-precursor acute lymphoblastic leukemia with normal karyotypes or without cytogenetic results.

Alvarez Y, Gaitán S, Perez A, Bastida P, Ortega JJ, Dastugue N, Robert A, Aventín A, Badell I, Guitart M, Melo M, Caballín MR, Coll MD.

Cancer Genet Cytogenet. 2004 Jul 1;152(1):77-80.

PMID:
15193447
15.

Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.

Ortega JJ, Díaz de Heredia C, Olivé T, Bastida P, Llort A, Armadans L, Torrabadella M, Massuet L.

Haematologica. 2003 Mar;88(3):290-9.

16.

AML1 amplification in a child with acute lymphoblastic leukemia.

Alvarez Y, Coll MD, Bastida P, Ortega JJ, Caballín MR.

Cancer Genet Cytogenet. 2003 Jan 1;140(1):58-61. Review.

PMID:
12550760
17.

Cultures of myeloid progenitor cells in pediatric essential thrombocythemia.

Florensa L, Zamora L, Besses C, Ortega JJ, Bastida P, Toll T, Mayayo P, Espinet B, Solé F, Serrano S, Woessner S.

Leukemia. 2002 Sep;16(9):1876-7. No abstract available.

18.

Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.

Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF; PETHEMA Group, Spanish Society of Hematology.

Haematologica. 2002 Feb;87(2):154-66.

19.

Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.

Ortega JJ, Ribera JM, Oriol A, Bastida P, González ME, Calvo C, Egurbide I, Hernández Rivas JM, Rivas C, Alcalá A, Besalduch J, Maciá J, Gardella S, Carnero M, Lite JM, Casanova F, Martinez M, Fontanillas M, Feliu E, San Miguel JF; PETHEMA Group, Spanish Society of Hematology. Programa para el Estudio y Tratamiento de las Hemopatías Malignas.

Haematologica. 2001 Jun;86(6):586-95.

20.

Results of intensive chemotherapy in children with juvenile chronic myelomonocytic leukemia: a pilot study.

Díaz de Heredia C, Ortega JJ, Coll MT, Bastida P, Olivé T.

Med Pediatr Oncol. 1998 Dec;31(6):516-20.

PMID:
9835905
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk